Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomes

Clicks: 12
ID: 334093
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #276 of 288 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 288 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Sodium-glucose cotransporter-2 (SGLT2) inhibitors are agents originally developed as glucose-lowering drugs but now widely used to improve cardiorenal outcomes, including in patients with heart failure and chronic kidney disease regardless of diabetes status. However, their exact mode of action remains unclear. Here, we investigated the association of loss-of-function (LoF) and other rare coding variants in the SLC5A2 gene, as a genetic model of altered SGLT2 function, with 13 cardiometabolic and renal traits and clinical outcomes. Methods and results A total of 442 570 European ancestry participants from the UK Biobank with exome sequence and phenotype data were included. We applied SAIGE-GENE+ for gene-based and single-variant association tests in the full study population and in individuals with heart failure, renal failure, and type 2 diabetes (T2D). A total of 52 LoF variants in SLC5A2 were identified. Rare variants in SLC5A2 were associated with decreased uric acid (PCauchy = 4.98 × 10−13) and with increased haematocrit (PCauchy = 1.67 × 10−5), haemoglobin (PCauchy = 1.60 × 10−5), and estimated glomerular filtration rate (PCauchy = 9.88 × 10−4). One frameshift variant (rs267607067) was significantly associated with increased haemoglobin (β = 0.33 [95% CI 0.15–0.51]; P-value = 2.40 × 10−4) and another (rs768095044) with decreased uric acid (β = −0.31 [95% CI −0.49 to −0.13]; P-value = 4.22 × 10−4). In patients with T2D, the rare variants within SLC5A2 were also associated with a lower probability of having heart failure (PCauchy = 4.00 × 10−4). Conclusion Rare genetic variants in SLC5A2 were associated with increased haemoglobin and decreased uric acid. These variants were also associated with a lower probability of heart failure among participants with T2D, providing tentative genetic support for a cardioprotective effect of SGLT2 inhibition.
Reference Key
openalex_W7223684933 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Siqi Wang, Ilja Maria Nolte, Dion Groothof, Hailun Qin, Stephan J. L. Bakker, Pim van der Harst, Harold Snieder
Are you one of these authors? Claim your profile
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag539
URL
https://doi.org/10.1093/eurjpc/zwag539
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.